Why Novavax Stock Got a Boost Today

·1 min read

Shares of Novavax (NASDAQ: NVAX) were up by around 8.4% on Tuesday morning as of 10:31 a.m. ET thanks to regulators at the European Commission ruling that the conditional marketing authorization (CMA) for the biotech's coronavirus vaccine, Nuvaxovid, could be expanded to include people between the ages of 12 and 17. This green light from regulators will likely enable the company to capture more revenue from sales to EU governments, who could be keen to purchase additional doses of the shot to inoculate their adolescent populations. As the first protein-based coronavirus vaccine to be commercialized in Europe, it'll also provide vaccine-hesitant parents in the EU with another option for their children, which might lead to a small increase in demand for doses.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting